Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

被引：0

作者：

Stefanie Noepel-Duennebacke

Hendrik Juette

Karsten Schulmann

Ulrich Graeven

Rainer Porschen

Jan Stoehlmacher

Susanna Hegewisch-Becker

Arne Raulf

Dirk Arnold

Anke Reinacher-Schick

Aandrea Tannapfel

机构：

[1] St. Josef-Hospital,Department for Hematology, Oncology und Palliative Care

[2] Ruhr-University,Institute of Pathology

[3] Ruhr-University Bochum,Department for Hematology and Oncology

[4] Klinikum Hochsauerland,Department for Hematology, Oncology and Gastroenterology

[5] Kliniken Maria-Hilf Mönchengladbach,Medical Department

[6] Klinikum Bremen-Ost,Center for Protein Diagnostics, Bioinformatics Group, Faculty of Biology and Biotechnology

[7] Individuelle Krebsberatung,Asklepios Cancer Center, Department for Hematology, Oncology and Palliative Care

[8] HOPE—Practice for Oncology,undefined

[9] Ruhr-University,undefined

[10] Asklepios Klinikum Altona Hamburg,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷

关键词：

Metastatic colorectal cancer; Immunoscore; PD-L1; Microsatellite instability; Bevacizumab; Overall survival;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3063 / 3072

页数：9

共 1 条